Duke University researchers report that damaged peripheral nerves can be revived using a new therapeutic approach targeting chronic pain at its source rather than masking symptoms with opioids or general analgesics alone.
The method combines molecular factors that restore mitochondrial function in injured axons with localized delivery techniques minimizing systemic exposure. Animal models showed restored nerve conduction and reduced pain behaviors lasting beyond treatment windows.
Chronic pain affects tens of millions of Americans following surgery, diabetes or trauma, contributing to disability and opioid dependence when inadequately managed. Current neuromodulation devices help subsets of patients but require invasive implantation.
Duke teams are negotiating investigational new drug applications with regulators to advance first-in-human safety studies if toxicology packages satisfy requirements. Biotech licensing discussions include potential partnerships with pain specialty pharmaceutical firms.
Independent pain clinicians welcomed mechanistic focus on nerve repair but noted translation history includes many preclinical successes that failed in clinical endpoints due to human anatomy complexity. Patient advocacy groups emphasized need for diverse trial enrollment reflecting gender differences in pain reporting.
Results were summarized in ScienceDaily health medicine reporting on May 25, 2026.
Pain management societies said nerve-repair strategies that reduce opioid reliance align with federal prescribing guidelines updated after years of overdose mortality concerns.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/